Where I see patients (1)
Selected research
- 
							New targets and new drugs for hepatobiliary cancers.
							Journal of hepatology
- 
							PepTCR-Net: prediction of multi-class antigen peptides by T-cell receptor sequences with deep learning.
							Briefings in bioinformatics
- 
							TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors.
							Cell reports. Medicine
Clinical trials
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lun...
according to RECIST v 1.1 by investigator assessment from the date of treatment start until the earliest date of disease progression, death, or last evaluable tumour assessment before start of subsequent anti-cancer therapy, loss ...
Recruiting
 
					
				
 
														 
														 
														 
														 
														 
				
			